Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the fourth quarter of 2026 SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today provided business updates and reported financial results for the third quarter of 2024. "The third quarter was marked by steady execution across the portfolio, with the POTENTIATE and STAR

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in the 2024 Guggenheim Global Healthcare Conference. A fireside chat session is scheduled for Tuesday, November 12, 2024, in Boston, MA, at 2:30 p.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website. About Boundless BioBoundless Bio is a cl

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does not plan to hire a successor CFO at this time; David Hinkle, Senior Vice President, Finance and Controller, will maintain responsibility for the company's Finance operations and assume the roles of principal financial and accounting officer. "On behalf of the company and Board, I want to extend m

SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in the 2024 Cantor Global Healthcare Conference. A fireside chat session is scheduled for Wednesday, September 18, 2024, in New York, NY, at 10:20 a.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's websit

BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825 STARMAP clinical trial ongoing with initial proof-of-concept data expected in the second half of 2025 ECHO ecDNA diagnostic analytically validated and IRB-approved for use as a clinical trial assay in BBI-355 POTENTIATE trial Streamlined operations expected to extend operating runway into the fourth quarter of 2026 SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformat

Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The fireside chat session is scheduled for Wednesday, June 12, in Miami, FL, at 3:20 p.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website. About Boundless Bio

10-Q - Boundless Bio, Inc. (0001782303) (Filer)

8-K - Boundless Bio, Inc. (0001782303) (Filer)

8-K - Boundless Bio, Inc. (0001782303) (Filer)

8-K - Boundless Bio, Inc. (0001782303) (Filer)

8-K - Boundless Bio, Inc. (0001782303) (Filer)

10-Q - Boundless Bio, Inc. (0001782303) (Filer)

3 - Boundless Bio, Inc. (0001782303) (Issuer)

4 - Boundless Bio, Inc. (0001782303) (Issuer)

4 - Boundless Bio, Inc. (0001782303) (Issuer)

4 - Boundless Bio, Inc. (0001782303) (Issuer)

4 - Boundless Bio, Inc. (0001782303) (Issuer)

4 - Boundless Bio, Inc. (0001782303) (Issuer)

4 - Boundless Bio, Inc. (0001782303) (Issuer)

4 - Boundless Bio, Inc. (0001782303) (Issuer)

SC 13D - Boundless Bio, Inc. (0001782303) (Subject)